• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen.

作者信息

Robin Marie, Nibourel Olivier, Tournaire Martin, Michonneau David, Preudhomme Claude, Verbanck Marie, Xhaard Aliénor, Adès Lionel, Sicre de Fontbrune Flore, Sébert Marie, Fenaux Pierre, Socié Gérard, Peffault de Latour Régis, Curis Emmanuel

机构信息

Hématologie-greffe, hôpital Saint-Louis, Université de Paris Cité, Paris, France.

Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 -CANTHER -Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.

出版信息

Bone Marrow Transplant. 2024 Sep;59(9):1309-1312. doi: 10.1038/s41409-024-02314-2. Epub 2024 May 23.

DOI:10.1038/s41409-024-02314-2
PMID:38783124
Abstract
摘要

相似文献

1
Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen.在接受减低强度预处理方案后的异基因造血干细胞移植的骨髓增生异常综合征患者中进行分子改变监测。
Bone Marrow Transplant. 2024 Sep;59(9):1309-1312. doi: 10.1038/s41409-024-02314-2. Epub 2024 May 23.
2
On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation.代表 SFGM-TC：异基因干细胞移植治疗高危骨髓增生异常综合征时降低强度与高强度预处理的回顾性比较
Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):34-43. doi: 10.1016/j.clml.2021.07.027. Epub 2021 Jul 31.
3
Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.接受减低强度预处理方案的骨髓增生异常综合征患者的移植前低甲基化药物治疗
Biol Blood Marrow Transplant. 2014 Sep;20(9):1260-1. doi: 10.1016/j.bbmt.2014.07.006. Epub 2014 Jul 11.
4
The Art of Transplantation: Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation.移植艺术：异基因造血干细胞移植的预处理强度。
Biol Blood Marrow Transplant. 2019 Mar;25(3):e71-e72. doi: 10.1016/j.bbmt.2018.12.067. Epub 2018 Dec 15.
5
CD34+ cell dose in allogeneic transplantation: weight considerations.异基因移植中CD34+细胞剂量：体重因素考量
Biol Blood Marrow Transplant. 2015 Jan;21(1):196. doi: 10.1016/j.bbmt.2014.09.018. Epub 2014 Sep 28.
6
[Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].[减低强度预处理异基因造血干细胞移植治疗骨髓增生异常综合征的研究进展 - 综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):969-74.
7
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.低强度预处理用于骨髓增生异常综合征和急性髓系白血病的异基因造血干细胞移植
Curr Opin Oncol. 2007 Nov;19(6):660-6. doi: 10.1097/CCO.0b013e3282f0e188.
8
CD34 Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .CD34 细胞选择与减低强度预处理和非清髓移植在年龄 >50 岁的急性髓系白血病和骨髓增生异常综合征患者中的异基因造血细胞移植。
Biol Blood Marrow Transplant. 2018 May;24(5):964-972. doi: 10.1016/j.bbmt.2017.12.804. Epub 2018 Jan 2.
9
Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?哪些骨髓增生异常综合征患者应接受异基因干细胞移植，以及我们应该何时进行移植？
Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S43-9. doi: 10.1016/j.clml.2015.04.002.
10
Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study.老年晚期骨髓增生异常综合征患者减低剂量预处理的异基因造血细胞移植：一项全国性研究。
Br J Haematol. 2015 Feb;168(3):463-6. doi: 10.1111/bjh.13124. Epub 2014 Sep 17.

本文引用的文献

1
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.骨髓增生异常综合征的分子国际预后评分系统
NEJM Evid. 2022 Jul;1(7):EVIDoa2200008. doi: 10.1056/EVIDoa2200008. Epub 2022 Jun 12.
2
Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.迈向骨髓增生异常综合征中可测量残留疾病的概念化。
Blood Adv. 2023 Aug 22;7(16):4381-4394. doi: 10.1182/bloodadvances.2023010098.
3
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
分子国际预后评分系统在骨髓增生异常综合征中的真实世界验证。
J Clin Oncol. 2023 May 20;41(15):2827-2842. doi: 10.1200/JCO.22.01784. Epub 2023 Mar 17.
4
The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation.清髓性异基因造血干细胞移植后，流式细胞术定义的微小残留病早期检测及基因突变清除对骨髓增生异常综合征患者的预后价值
Front Oncol. 2021 Aug 5;11:700234. doi: 10.3389/fonc.2021.700234. eCollection 2021.
5
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.基于供者可用性的 50-75 岁中高危骨髓增生异常综合征患者减低强度异基因造血干细胞移植的生物学分配试验
J Clin Oncol. 2021 Oct 20;39(30):3328-3339. doi: 10.1200/JCO.20.03380. Epub 2021 Jun 9.
6
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.采用二代测序技术利用DTA和非DTA突变对急性髓系白血病患者进行移植后微小残留病监测。
Blood Adv. 2021 May 11;5(9):2294-2304. doi: 10.1182/bloodadvances.2021004367.
7
Simultaneous Monitoring of Mutation and Chimerism Using Next-Generation Sequencing in Myelodysplastic Syndrome.使用下一代测序技术在骨髓增生异常综合征中同时监测突变和嵌合体状态
J Clin Med. 2019 Nov 28;8(12):2077. doi: 10.3390/jcm8122077.
8
Mutation Clearance after Transplantation for Myelodysplastic Syndrome.骨髓增生异常综合征患者移植后的基因突变清除
N Engl J Med. 2018 Sep 13;379(11):1028-1041. doi: 10.1056/NEJMoa1804714.
9
Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.急性髓系白血病或骨髓增生异常综合征移植后复发患者接受阿扎胞苷治疗期间系列骨髓样本的突变分析。
Haematologica. 2017 Jun;102(6):e216-e218. doi: 10.3324/haematol.2016.162909. Epub 2017 Feb 16.
10
HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM.HLA 匹配的异基因造血干细胞移植改善高危骨髓增生异常综合征的预后：代表 SFGM-TC 和 GFM 的前瞻性研究。
Leukemia. 2015 Jul;29(7):1496-501. doi: 10.1038/leu.2015.37. Epub 2015 Feb 13.